Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

February 28, 2024 23:30 ET | Source: Arcutis Biotherapeutics, Inc.

Arcutis Announces Pricing of $150 Million Public Offering

Arcutis today announced the pricing of its underwritten public offering of common stock.
February 28, 2024 16:10 ET | Source: Arcutis Biotherapeutics, Inc.

Arcutis Announces Proposed Public Offering

Arcutis today announced the commencement of an underwritten public offering of $150.0 million of shares of its common stock
February 28, 2024 16:00 ET | Source: Arcutis Biotherapeutics, Inc.

Arcutis and Sato Announce Strategic Collaboration and Licensing Agreement for Topical Roflumilast in Japan

Arcutis and Sato today announced that the companies have entered into a strategic collaboration and licensing agreement for topical roflumilast in Japan.
February 27, 2024 05:50 ET | Source: Arcutis Biotherapeutics, Inc.

Arcutis Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Arcutis today reported financial results for the quarter and year ended December 31, 2023, and provided a business update.
February 16, 2024 08:00 ET | Source: Arcutis Biotherapeutics, Inc.

Arcutis to Report Fourth Quarter and Full Year 2023 Financial Results

Arcutis today announced that it will report its fourth quarter and full year financial results and provide a business update on Tuesday, February 27, 2024.
February 06, 2024 16:00 ET | Source: Arcutis Biotherapeutics, Inc.

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

WESTLAKE VILLAGE, Calif., Feb. 06, 2024 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in...
January 31, 2024 08:00 ET | Source: Arcutis Biotherapeutics, Inc.

Arcutis to Present at the Guggenheim Healthcare Talks – 6th Annual Biotechnology Conference

Arcutis today announced that Arcutis management will participate in the Guggenheim Healthcare Talks – 6th Annual Biotechnology Conference.
January 29, 2024 08:00 ET | Source: Arcutis Biotherapeutics, Inc.

Journal of the American Academy of Dermatology Publishes ZORYVE (roflumilast) Foam, 0.3% Results for Seborrheic Dermatitis from Pivotal Phase 3 Trial

Arcutis today announced that JAAD published positive results from the pivotal Phase 3 STRATUM trial evaluating ZORYVE (roflumilast) foam, 0.3%.
January 22, 2024 08:00 ET | Source: Arcutis Biotherapeutics, Inc.

ZORYVE® (roflumilast) Topical Foam, 0.3%, for the Treatment of Seborrheic Dermatitis Launches in the United States

Arcutis today announced the launch of ZORYVE® (roflumilast) topical foam, 0.3%, in the United States for the treatment of seborrheic dermatitis
January 14, 2024 04:00 ET | Source: Arcutis Biotherapeutics, Inc.

ZORYVE® (Roflumilast) Topical Foam, 0.3% Clears Seborrheic Dermatitis in Individuals Who Previously Reported an Inadequate Response to Topical Steroids

Arcutis today announced a new subgroup analysis in adults and adolescents with seborrheic dermatitis from STRATUM study